| abstract |
The present invention relates to an agent for combination therapy, preferably for the use in the prophylactic and/or therapeutic treatment of in particular inflammatory diseases of the upper respiratory tract, preferably the nose and/or the paranasal sinuses, preferably rhinitis, or for the use in the prophylactic and/or therapeutic treatment of in particular inflammatory diseases of the eye. The agent for combination therapy comprises at least a vitamin D receptor agonist (VDA) and at least a vasoconstrictor, in particular alpha sympathomimeticum, preferably alpha-1 sympathomimeticum, or its physiologically acceptable salts. |